Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Kaneda-Nakashima, Kazuko*; Shirakami, Yoshifumi*; Kadonaga, Yuichiro*; Watabe, Tadashi*; Oe, Kazuhiro*; Yin, X.*; Haba, Hiromitsu*; Shirasaki, Kenji*; Kikunaga, Hidetoshi*; Tsukada, Kazuaki; et al.
International Journal of Molecular Sciences (Internet), 25(2), p.933_1 - 933_14, 2024/01
Times Cited Count：1 Percentile：92.20(Biochemistry & Molecular Biology)
At]NaAt and [
I]NaI in an NIS-expressing thyroid cancer mouse modelWatabe, Tadashi*; Liu, Y.*; Kaneda, Kazuko*; Sato, Tatsuhiko; Shirakami, Yoshifumi*; Oe, Kazuhiro*; Toyoshima, Atsushi*; Shimosegawa, Eku*; Wang, Y.*; Haba, Hiromitsu*; et al.
International Journal of Molecular Sciences (Internet), 23(16), p.9434_1 - 9434_11, 2022/08
Times Cited Count：9 Percentile：82.33(Biochemistry & Molecular Biology)In this study, we compare the therapeutic effect between [At]NaAt and [I]NaI. In vitro analysis of double-stranded DNA break (DSB) and colony formation assay were performed using K1-NIS cells. [At]NaAt induced higher numbers of DSBs and had a reduced colony formation than [I]NaI. In K1-NIS mice, dose-dependent therapeutic effects were observed in both [At]NaAt and [I]NaI. The superior therapeutic effect of [At]NaAt suggests the promising clinical applicability of targeted alpha therapy using [At]NaAt in patients with differentiated thyroid cancer refractory to standard [I]NaI treatment.
Sato, Tatsuhiko; Furuta, Takuya; Liu, Y.*; Naka, Sadahiro*; Nagamori, Shushi*; Kanai, Yoshikatsu*; Watabe, Tadashi*
EJNMMI Physics (Internet), 8, p.4_1 - 4_16, 2021/01
Times Cited Count：13 Percentile：83.50(Radiology, Nuclear Medicine & Medical Imaging)An individual dosimetry system including the function for calculating EQDX was developed based on PHITS coupled with the microdosimetric kinetic model. It enables us to predict the therapeutic and side effects of TAT based on the clinical data largely available from conventional external radiotherapy.
Kudo, Kenji; Kawatsuma, Shinji; Rindo, Hiroshi; Watabe, Kozo; Tomii, Hiroyuki; Shiraishi, Kunio; Yagi, Naoto; Fukushima, Tadashi; Zaitsu, Tomohisa
Proceedings of 14th International Conference on Nuclear Engineering (ICONE-14) (CD-ROM), 8 Pages, 2006/07
Japan Atomic Energy Research Institute (JAERI) played a leading role in basic research in the field of atomic energy research and development, while Japan Nuclear Cycle Development Institute (JNC) did a major role in FBR cycle development and high level waste disposal. Following the Government's decision in December 2001, JAERI and JNC was merged as of October 1st, 2005. The new organization, Japan Atomic Energy Agency (JAEA), is an institute for comprehensive R&D for atomic energy, and is the largest research and development institute among Governmental R&D organizations. Its missions are basic research on atomic energy, R&D for nuclear fuel cycle, decommissioning of own facilities and disposal of waste, contribution to safety and non-proliferation, etc. The JAEA owns a number of nuclear facilities: research reactors such as JRR-2 and Joyo, prototype reactors such as ATR "Fugen" and FBR "Monju", fuel cycle plants such as Uranium Enrichment Demonstration Plant at Ningyo-Toge, MOX fuel plants at Tokai, Reprocessing Plant at Tokai, and Hot Laboratories such as JRTF and FMF. As a part of preparation of the mergence, JNC and JAERI have jointly developed a comprehensive cost estimation method for decommissioning, based on decommissioning and refurbishing experiences of JAERI and JNC. This method involves more estimation parameters from typical decommissioning activities than before, so as to make it more reliable. JAERI and JNC have estimated the total cost for decommissioning by using this method, and concluded that the cost would be 600 billion yen (approx. 5 billion USD).
Sato, Tatsuhiko; Furuta, Takuya; Sasaki, Hidetaka*; Watabe, Tadashi*
no journal, ,
The details of individual dosimetry system for targeted radionuclide therapy based on the PHITS code will be presented at the meeting.
Sato, Tatsuhiko; Furuta, Takuya; Sasaki, Hidetaka*; Watabe, Tadashi*
no journal, ,
Current status and prospects of dosimetry research for targeted radiotherapy will be reviewed at the meeting
Sato, Tatsuhiko; Furuta, Takuya; Sasaki, Hidetaka*; Watabe, Tadashi*
no journal, ,
The purpose of this study was to apply our dosimetry system, RT-PHITS (RadioTherapy package based on Particle and Heavy Ion Transport code System), to the clinical research of the targeted alpha therapy (TAT) performed in Osaka University.
